SUMMARY

“The site/location of prostate cancer evolves/moves over time, which has important management implications. Advanced prostate cancer is a disease that predominantly resides in the bones.” Approximately 90% of men with advanced prostate cancer will develop bone metastases, and the presence of bone metastases indicates a poor prognosis and a higher mortality. Multiple symptoms are associated with bone metastases, and these symptoms negatively impact quality of life.

Early detection of bone metastases can inform clinical decision-making and is dependent on laboratory, clinical, and patient symptom assessment. Strategies for the early identification of metastases in patients with prostate cancer have been recommended by the RADAR Group, and ALP plus PSA can be an effective tool for predicting risk of metastatic bone disease. Because mortality increases as the disease migrates from localized to multiple metastatic sites, it is important for clinicians to adjust their clinical approach as prostate cancer progresses.

PP-PF-ONC-CA-0118-1